Synthetically lethal nanoparticles for treatment of endometrial cancer

Kareem Ebeid, Xiangbing Meng, Kristina W. Thiel, Anh Vu Do, Sean M. Geary, Angie S. Morris, Erica L. Pham, Amaraporn Wongrakpanich, Yashpal S. Chhonker, Daryl J Murry, Kimberly K. Leslie, Aliasger K. Salem

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.

Original languageEnglish (US)
Pages (from-to)72-81
Number of pages10
JournalNature Nanotechnology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Paclitaxel
cancer
Nanoparticles
nanoparticles
lethality
Tumors
tumors
mutations
suppressors
viability
Heterografts
progressions
inhibitors
therapy
Cells
formulations
profiles
cells

ASJC Scopus subject areas

  • Bioengineering
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering
  • Materials Science(all)
  • Condensed Matter Physics
  • Electrical and Electronic Engineering

Cite this

Ebeid, K., Meng, X., Thiel, K. W., Do, A. V., Geary, S. M., Morris, A. S., ... Salem, A. K. (2018). Synthetically lethal nanoparticles for treatment of endometrial cancer. Nature Nanotechnology, 13(1), 72-81. https://doi.org/10.1038/s41565-017-0009-7

Synthetically lethal nanoparticles for treatment of endometrial cancer. / Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W.; Do, Anh Vu; Geary, Sean M.; Morris, Angie S.; Pham, Erica L.; Wongrakpanich, Amaraporn; Chhonker, Yashpal S.; Murry, Daryl J; Leslie, Kimberly K.; Salem, Aliasger K.

In: Nature Nanotechnology, Vol. 13, No. 1, 01.01.2018, p. 72-81.

Research output: Contribution to journalArticle

Ebeid, K, Meng, X, Thiel, KW, Do, AV, Geary, SM, Morris, AS, Pham, EL, Wongrakpanich, A, Chhonker, YS, Murry, DJ, Leslie, KK & Salem, AK 2018, 'Synthetically lethal nanoparticles for treatment of endometrial cancer', Nature Nanotechnology, vol. 13, no. 1, pp. 72-81. https://doi.org/10.1038/s41565-017-0009-7
Ebeid K, Meng X, Thiel KW, Do AV, Geary SM, Morris AS et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nature Nanotechnology. 2018 Jan 1;13(1):72-81. https://doi.org/10.1038/s41565-017-0009-7
Ebeid, Kareem ; Meng, Xiangbing ; Thiel, Kristina W. ; Do, Anh Vu ; Geary, Sean M. ; Morris, Angie S. ; Pham, Erica L. ; Wongrakpanich, Amaraporn ; Chhonker, Yashpal S. ; Murry, Daryl J ; Leslie, Kimberly K. ; Salem, Aliasger K. / Synthetically lethal nanoparticles for treatment of endometrial cancer. In: Nature Nanotechnology. 2018 ; Vol. 13, No. 1. pp. 72-81.
@article{5a056921f28c4812819c22f86784850e,
title = "Synthetically lethal nanoparticles for treatment of endometrial cancer",
abstract = "Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.",
author = "Kareem Ebeid and Xiangbing Meng and Thiel, {Kristina W.} and Do, {Anh Vu} and Geary, {Sean M.} and Morris, {Angie S.} and Pham, {Erica L.} and Amaraporn Wongrakpanich and Chhonker, {Yashpal S.} and Murry, {Daryl J} and Leslie, {Kimberly K.} and Salem, {Aliasger K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41565-017-0009-7",
language = "English (US)",
volume = "13",
pages = "72--81",
journal = "Nature Nanotechnology",
issn = "1748-3387",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Synthetically lethal nanoparticles for treatment of endometrial cancer

AU - Ebeid, Kareem

AU - Meng, Xiangbing

AU - Thiel, Kristina W.

AU - Do, Anh Vu

AU - Geary, Sean M.

AU - Morris, Angie S.

AU - Pham, Erica L.

AU - Wongrakpanich, Amaraporn

AU - Chhonker, Yashpal S.

AU - Murry, Daryl J

AU - Leslie, Kimberly K.

AU - Salem, Aliasger K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.

AB - Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.

UR - http://www.scopus.com/inward/record.url?scp=85036544040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036544040&partnerID=8YFLogxK

U2 - 10.1038/s41565-017-0009-7

DO - 10.1038/s41565-017-0009-7

M3 - Article

C2 - 29203914

AN - SCOPUS:85036544040

VL - 13

SP - 72

EP - 81

JO - Nature Nanotechnology

JF - Nature Nanotechnology

SN - 1748-3387

IS - 1

ER -